

Hormonal Therapy for Inguinal Endometriosis

Shiomi Ushida, Satoshi Ichigo, Hiroshi Takagi, Kazutoshi Matsunami, Hazuki Kagawa, Ichiro Kawabata and Atsushi Imai*

Department of Obstetrics and Gynecology, Matsunami General Hospital, Japan

***Corresponding author:** Atsushi Imai, Department of Obstetrics and Gynecology, Matsunami General Hospital, 185-1 Dendai, Kasamatsu, Gifu 501-6062, Japan

ARTICLE INFO

Received: 📅 June 26, 2023

Published: 📅 July 14, 2023

Citation: Shiomi Ushida, Satoshi Ichigo, Hiroshi Takagi, Kazutoshi Matsunami, Hazuki Kagawa, Ichiro Kawabata and Atsushi Imai. Hormonal Therapy for Inguinal Endometriosis. Biomed J Sci & Tech Res 51(3)-2023. BJSTR. MS.ID.008118.

ABSTRACT

Inguinal endometriosis is an infrequent extragenital manifestation of endometriosis. Optimal management involves the radical surgical excision of the lesion, supplemented by hormone therapy. Recent case reports and retrospective analyses have indicated that hormone therapy utilizing gonadotropin-releasing hormone agonist, dienogest, or oral contraceptives is the preferred initial therapeutic approach when the patient declines surgery.

Abbreviations: GnRHa: Gonadotropin-Releasing Hormone Agonist, OC: Oral Contraceptives, MR: Magnetic Resonance

Introduction

Endometriosis is characterized by the presence of endometriosis-like tissues outside the uterine cavity [1,2]. It predominantly develops lesions in the pelvic gonadal organs and rectovaginal pouch, less commonly affecting the gastrointestinal and urinary tracts, and rarely occurring at distant sites such as the umbilicus and thoracic cavity [3,4]. Inguinal endometriosis, an uncommon presentation of extra-pelvic endometriosis, typically manifests as a tender, fixed inguinal mass of small size. This condition exhibits changes in mass size and pain that correlate with the menstrual cycle. It is observed in approximately 0.5% of endometriosis cases [5,6]. Surgical intervention has been frequently reported as the optimal diagnostic and therapeutic strategy [7-9], and, therefore, there is limited literature on hormonal treatment.


Hormonal Treatment

(Table 1) provides a summary of reported cases of inguinal endometriosis managed through hormonal therapy. Tanaka and Umesaki

reported complete remission of catamenial right inguinal pain and right shoulder joint pain associated with extraperitoneal endometriosis following gonadotropin-releasing hormone agonist (GnRHa) therapy. Several cycles of oral contraceptive (OC) therapy exhibited inadequate effects on her both pain [10]. In a retrospective case series, 8 patients with inguinal endometriosis received hormonal treatment without surgery. Dienogest demonstrated pain and swelling improvement in 75% (3 out of 4) cases, although symptoms persisted in one case. Pain improved in 1 out of 4 patients receiving OC therapy. Among the 3 cases showing no improvement, all experienced persisting pain. A small subset of patients did not receive any treatment [6,11]. We encountered a critical case featuring a painful mass in the right inguinal area, particularly during menstrual cycles. Three administrations of gonadotropin-releasing hormone agonist (1.88mg) with a 4-week interval led to complete remission of inguinal endometriosis and significant improvement of the ovarian lesion (Figure 1) (manuscript in preparation).

Table 1: Reported cases of inguinal endometriosis with hormonal therapy.

No.	Patient Age	Symptoms	Medicine	Ref.
1	41	Right inguinal mass and pain	Dienogest	[11]
2	43	Right inguinal mass and pain	Dienogest	[11]
3	42	Right inguinal mass and pain	Dienogest	[11]
4	43	Right inguinal mass and pain	Dienogest	[11]
5	27	Right inguinal mass and pain	OC	[11]
6	34	Right inguinal mass and pain	OC	[11]
7	31	Left inguinal mass and pain	OC	[11]
8	29	Right inguinal mass and pain	OC	[11]
9	47	Right inguinal pain and right shoulder pain	GnRHa	[10]
Current case	41	Right inguinal mass and pain	GnRHa	

**Figure 1:**

A. A case of inguinal endometriosis. A 41-year-old woman presented with a painful mass in her right inguinal area, particularly during menstrual cycles. Magnetic resonance imaging (MRI) sagittal images (T2-weighted) revealed a cystic mass (2 by 2 cm) in the right inguinal area (yellow arrow) and an ovarian lesion (white arrow).

B. Three administrations of gonadotropin-releasing hormone agonist (1.88mg) with a 4-week interval led to complete remission of inguinal endometriosis and significant improvement of the ovarian lesion.

Discussion

Theoretically, hormonal therapy, rather than surgical intervention, may be considered the primary choice due to the multifocal nature of endometriosis in most patients [12,13]. In cases of severe inguinal endometriosis where surgery is not desired, the ideal medicinal treatment should possess prolonged, curative, and safe properties capable of reducing endometriotic lesions. OC is highly safe medications with minimal adverse effects [14,15], making them a current first-choice option for maintenance therapy after remission-induction. However, OC therapy exhibits a slow onset of action, rendering it unsuitable for rapidly ameliorating symptoms. GnRHa therapy can promptly induce

complete remission. Inguinal endometriosis is challenging to identify and often mistaken for more common conditions such as hernias, soft tissue tumors, lymphadenopathy, cysts, granulomas and hydroceles. Catamenial symptoms (e.g., variations in mass size and tenderness) and magnetic resonance (MR) imaging findings can raise suspicion for inguinal endometriosis [4]. Frequently, patients undergo surgical procedures with a preoperative diagnosis of hernia, and endometriosis is incidentally discovered or identified through histologic examination [6,16]. Surgical excision may be the treatment of choice for inguinal endometriosis, but hormone medications can alleviate symptoms associated with endometriosis and serve as an alternation for patients who do not want surgery.

Conflict of Interest

The authors declare that they have no conflict of interest.

References

- Vercellini P, Viganò P, Somigliana E, Fedele L (2014) Endometriosis: pathogenesis and treatment. *Nat Rev Endocrinol* 10(5): 261-275.
- Zondervan KT, Becker CM, Missmer SA (2020) Endometriosis. *N Engl J Med* 382(13): 1244-1256.
- Hirata T, Koga K, Osuga Y (2020) Extra-pelvic endometriosis: a review. *Reprod Med Biol* 19(4): 323-333.
- Dallaudière B, Salut C, Hummel V, Pouquet M, Piver P, et al. (2013) MRI atlas of ectopic endometriosis. *Diagn Interv Imaging* 94(3): 263-280.
- Licheri S, Pisano G, Erdas E, Ledda S, Casu B, et al. (2005) Endometriosis of the round ligament: description of a clinical case and review of the literature. *Hernia* 9(3): 294-297.
- Dalkalitsis A, Salta S, Tsakiridis I, Dagklis T, Kalogiannidis I, et al. (2022) Inguinal endometriosis: A systematic review. *Taiwan J Obstet Gynecol* 61(1): 24-33.
- Niitsu N, Tsumura H, Kanehiro T, Yamaoka, H Taogoshi H, et al. (2019) Clinical characteristics and surgical treatment for inguinal endometriosis in young women of reproductive age. *Dig Surg* 36(2): 166-172.
- Wolfhagen N, Simons NE, de Jong KH, van Kesteren PJM, MP Simons MP (2018) Inguinal endometriosis, a rare entity of which surgeons should be aware: clinical aspects and long-term follow-up of nine cases. *Hernia* 22(5): 881-886.
- Singh KK, Lessells AM, Adam DJ, Jordan C, Miles WF, et al. (1995) Presentation of endometriosis to general surgeons: a 10-year experience. *Br J Surg* 82(10): 1349-1351.
- Tanaka T, Umesaki N (2009) Complete remission of OC-resistant catamenial shoulder joint pain and inguinal pain associated with extraperitoneal endometriosis following personalized GnRH agonist therapy. *Clin Exp Obstet Gynecol* 36(1): 46-48.
- Arakawa T, Hirata T, Koga K, Neriishi K, Fukuda S, et al. (2019) Clinical aspects and management of inguinal endometriosis: A case series of 20 patients. *J Obstet Gynaecol Res* 45(10): 2029-2036.
- Khetan N, Torkington J, Watkin A, Jamison MH, Humphreys WV (1999) Endometriosis: presentation to general surgeons. *Ann R Coll Surg Engl* 81(4): 255-259.
- Hirata A, Koga K, Osuga Y (2020) Extra-pelvic endometriosis: a review. *Reprod Med Biol* 19(4): 323-333.
- Vercellini P, Buggio L, Frattaruolo MP, Borghi A, Dridi D, et al. (2018) Medical treatment of endometriosis-related pain. *Best Pract Res Clin Obstet Gynaecol*. 51: 68-91.
- Hee L, Kettner LO, Vejtorp M (2013) Continuous use of oral contraceptives: an overview of effects and side-effects. *Acta Obstet Gynecol Scand* 92(2): 125-136.
- Mu B, Zhang Z, Liu C, Zhang K, Li S, et al. (2021) Long term follow-up of inguinal endometriosis. *BMC Womens Health* 21(1): 90.

ISSN: 2574-1241

DOI: 10.26717/BJSTR.2023.51.008118

Atsushi Imai. Biomed J Sci & Tech Res



This work is licensed under Creative Commons Attribution 4.0 License

Submission Link: <https://biomedres.us/submit-manuscript.php>



Assets of Publishing with us

- Global archiving of articles
- Immediate, unrestricted online access
- Rigorous Peer Review Process
- Authors Retain Copyrights
- Unique DOI for all articles

<https://biomedres.us/>